BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis

Company Overview

BioCryst Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes oral medicines for rare diseases. The company focuses on small-molecule therapies designed to address diseases with significant unmet medical needs, including hereditary angioedema and complement-mediated disorders.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral plasma kallikrein inhibitor used to prevent attacks of hereditary angioedema in adults and pediatric patients. The company also maintains a research and development pipeline focused on potential treatments for rare diseases, including therapies that target the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically worked on antiviral and enzyme-targeted medicines. Its research contributed to peramivir, an antiviral later marketed as Rapivab for the treatment of influenza. BioCryst markets its products in the United States and select international markets, while using regional partnerships and distribution arrangements to serve additional geographies. The company is led by President and Chief Executive Officer Jon Stonehouse.

Key Stats

• Today's Range: $7.92 to $8.20
• 50-Day Range: $8.12 to $10.59
• 52-Week Range: $6.00 to $11.22
• Volume: 6.14 million shs
• Average Volume: 5.89 million shs
• Market Capitalization: $2.09 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.50
• Consensus Rating: Moderate Buy

BioCryst Pharmaceuticals Stock Analysis - MarketRank™

BioCryst Pharmaceuticals scored higher than 47% of companies evaluated by MarketBeat, and ranked 538th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioCryst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

BioCryst Pharmaceuticals has a consensus price target of $20.50, representing about 150.9% upside from its current price of $8.17.

Amount of Analyst Coverage

BioCryst Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($2.28) to $0.69 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioCryst Pharmaceuticals is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioCryst Pharmaceuticals is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.18% of the float of BioCryst Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

BioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 7.29.

Change versus previous month

Short interest in BioCryst Pharmaceuticals has recently increased by 2.40%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioCryst Pharmaceuticals does not currently pay a dividend.

Dividend Growth

BioCryst Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.31

News Sentiment

BioCryst Pharmaceuticals has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for BioCryst Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

Only 4 people have searched for BCRX on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.80% of the stock of BioCryst Pharmaceuticals is held by insiders.

Percentage Held by Institutions

85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BCRX
• CIK: 882796
• Web: www.biocryst.com
• Phone: (919) 859-1302
• Fax: 919-859-1314
• Employees: 435
• Year Founded: 1986

Price Target and Rating

• Average Price Target for BioCryst Pharmaceuticals: $20.50
• High Price Target: $32.00
• Low Price Target: $9.00
• Potential Upside/Downside: +150.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $263.86 million
• Net Margins: -40.90%
• Pretax Margin: -40.53%
• Return on Equity: -86.89%
• Return on Assets: 66.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.32
• Quick Ratio: 2.29

Sales & Book Value

• Annual Sales: $874.84 million
• Price / Sales: 2.39
• Cash Flow: $1.24 per share
• Price / Cash Flow: 6.60
• Book Value: ($0.57) per share
• Price / Book: -14.33

Miscellaneous

• Outstanding Shares: 255,540,000
• Free Float: 245,825,000
• Market Cap: $2.09 billion
• Optionable: Optionable
• Beta: 0.55